Medtronic, Alnylam and CHDI will develop a drug-device combo

11/3/2010 | Mass High Tech (Boston)

Alnylam Pharmaceuticals will work with Medtronic and CHDI Foundation to develop ALN-HTT, an RNAi-based drug for Huntington's disease that can be delivered by Medtronic's implantable infusion device. CHDI will fund as much as 50% of requirements necessary for seeking regulatory approval of the drug-device combination. Medtronic and Alnylam will have an equal share in the partnership in the U.S.

View Full Article in:

Mass High Tech (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX